Clinical trials: Neuromyelitis Optica Spectrum Disorders
NMO Spectrum Disorder, Azathioprine Adverse Reaction
Monitoring of Azathioprine Metabolite Concentrations and Cytokine Levels in Neuromyelitis Optica Spectrum Disorder
Background: The pathogenesis of NMOSD has been linked to the cytokines interleukins (IL) -6, NOD-, LRR-and pyrin domain-containing 3 (NLRP3) and IL-18 that contribute to development of inflammatory reactionsmay.
- Trial name
- NCT05896605
- Testing
- Azathioprine
- Where
- China
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Neuromyelitis Optica Spectrum Disorders (NMOSD)
Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
Study Title: A National, Multicenter, Randomized Controlled Trial of the Modified Zipper Therapy in AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (ELITE Study) Brief Summary: The goal of this clinical trial is to…
- Trial name
- ELITE (NCT07420296)
- Testing
- Eculizumab administration, High-dose corticosteroid pulse therapy, Plasma exchange (PE)
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Tianjin Medical University General Hospital
Multiple Sclerosis, NMO Spectrum Disorder
Tongji NADs Cohort
Neurological Autoimmune Diseases (NADs) are disorders caused by abnormal immune system attacks on neural tissues, affecting multiple systems including the central nervous system, peripheral nervous system, and neuromuscular…
- Conditions
- Multiple Sclerosis, NMO Spectrum Disorder, Autoimmune Encephalitis, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
- Trial name
- NCT07333196
- Testing
- No active interventions
- Where
- China
- Volunteers
- 1,550 people
- Sponsor
- Tongji Hospital
Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
The objectives of this study are to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic and immunogenic profiles of satralizumab in participants with NMO and NMOSD.
- Trial name
- NCT02073279
- Testing
- Satralizumab
- Where
- 58 sites in United States, Bulgaria and 13 more
- Volunteers
- 95 people
- Sponsor
- Hoffmann-La Roche
Neuromyelitis Optica
C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation
The overall objective is to evaluate the tolerability/safety and preliminary efficacy of CINRYZE® (C1 esterase inhibitor [human]) as add-on therapy for treatment of acute optic neuritis and/or transverse myelitis in NMO and…
- Trial name
- NCT01759602
- Testing
- C1-esterase inhibitor (Cinryze)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Michael Levy
Optic Neuromyelitis Spectrum Disease
A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders
This is a phase II/III multicenter, randomized, double-blind, placebo-controlled study, to investigate the efficacy and safety of BAT4406F injection in patients with neuromyelitis optica lineage disease (NMOSD) who are positive…
- Trial name
- NCT06044350
- Testing
- BAT4406F Injection
- Where
- 45 sites in China
- Volunteers
- 162 people
- Sponsor
- Bio-Thera Solutions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
Antibody-mediated inflammatory diseases of the nervous system (also known as autoimmune diseases of the nervous system) are autoimmune diseases in which autoimmune cells and immune molecules attack the nervous system as the main…
- Conditions
- Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder, Myasthenia Gravis
- Trial name
- CARTinNS (NCT04561557)
- Testing
- CT103A cells, Cyclophosphamide and fludarabine
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tongji Hospital
Neuromyelitis Optica Spectrum Disorder
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab in pediatric participants with Neuromyelitis Optica Spectrum Disorder (NMOSD).
- Trial name
- NCT05346354
- Testing
- Ravulizumab
- Where
- 16 sites in United States, Canada and 5 more
- Volunteers
- 12 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Neuromyelitis Optica Spectrum Disorders (NMOSD)
A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSD
This study is a multicenter, prospective cohort study designed to enroll 50 NMOSD patients who receive Satralizumab treatment during the early phase of an NMOSD attack.
- Trial name
- SATURN (NCT07762872)
- Testing
- Satralizumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Junwei Hao, MD
Neuromyelitis Optica Spectrum Disorders
A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
To assess the efficacy and safety of Inebilizumab in Chinese adult patients with neuromyelitis optica spectrum disorders.
- Trial name
- NCT06212245
- Testing
- Inebilizumab
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Hansoh BioMedical R&D Company
NMO Spectrum Disorder, Spasticity, Muscle
A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders
The goal of this clinical trial is to evaluate the safety and efficacy of nabiximols, a cannabinoid spray, for the treatment of moderate to severe spasticity in adult patients with AQP4-IgG positive and antibody-negative NMOSD.
- Trial name
- SENS-NMO (NCT05974293)
- Testing
- Nabiximols
- Where
- United States
- Sponsor
- Michael, Levy M.D.,Ph.D.
Multiple Sclerosis, NMO Spectrum Disorder
National, Multicentric Registry Study on Neuroimmunological Diseases in China
The aim of this study is to establish a real-world clinical neuroimmune disease research cohort, to follow up and observe the prognosis of patients with different subtypes and subgroups, and to provide support for the treatment…
- Conditions
- Multiple Sclerosis, NMO Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Myasthenia Gravis
- Trial name
- NIDBase (NCT06443333)
- Testing
- Data collection and follow-up observation, Data collection
- Where
- China
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Neuromyelitis Optica Spectrum Disorder
Comparison of the Efficacy and Safety of Immunoadsorption and Plasma Exchange for Acute Attack of Refractory Neuromyelitis Optica Spectrum Disorders
Neuromyelitis optica spectrum disorder (NMOSD) is one common demyelinating disease of the central nervous system in young adults, with high rate of disability and recurrence, and poor natural course, which can cause a serious…
- Trial name
- CAMPUS (NCT04064944)
- Testing
- blood purification equipment
- Volunteers
- 144 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder
Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases
This is an uncontrolled, prospective, observational cohort study to assess the function of meningeal lymphatic drainage and dynamics of immune cells in patients with relapsing multiple sclerosis (RMS) or Neuromyelitis optica…
- Conditions
- Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, Demyelinating Diseases of the Central Nervous System
- Trial name
- OMNISCIENCE (NCT05414487)
- Testing
- Ofatumumab
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Tianjin Medical University General Hospital
Neuromyelitis Optica Spectrum Disorders (NMOSD), Multiple Sclerosis
Cohort Study on Neuroimmune Diseases in the Reproductive Age
Neuroimmune diseases are more prevalent among women of reproductive age. Studies have shown that neuroimmune diseases may impact fertility.
- Conditions
- Neuromyelitis Optica Spectrum Disorders (NMOSD), Multiple Sclerosis, Autoimmune Encephalitis, Myasthenia Gravis
- Trial name
- RANID (NCT07653984)
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Neuromyelitis Optica Spectrum Disorders (NMOSD), Neuropathic Pain
Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
This study is a multicenter, prospective, randomized, double-blind, placebo-controlled exploratory investigation conducted in China.
- Trial name
- TERMINATOR (NCT07699770)
- Testing
- Crisugabalin
- Where
- 10 sites in China
- Volunteers
- 110 people
- Sponsor
- Tang-Du Hospital
Neuromyelitis Optica Spectrum Disorder
Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders
This study is aimed to observe the effectiveness and safety of inebilizumab in the acute phase of neuromyelitis optica spectrum disorders.
- Trial name
- NCT05891379
- Testing
- Inebilizumab, oral immunosuppressant
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Xuanwu Hospital, Beijing
Autoimmune Disease
The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD
This is an open label, Multi-center，dose-escalation study in up to 18 participants with refractory NMOSD. This study aims to evaluate the safety and efficacy of universal CAR-T Cells targeting BCMA in the Treatment of refractory…
- Trial name
- NCT06633042
- Testing
- Universal BCMA-CD19 CART
- Volunteers
- 18 people
- Sponsor
- Bioray Laboratories
Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM)
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
A Phase 1 study of HBI0101 BCMA-CART in B-Cell Mediated Autoimmune Rheumatic Diseases. The goal of the study is evaluation of safety and identification of the maximum HBI0101 CART dose that may be administered safely to patients…
- Conditions
- Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
- Trial name
- NCT07085676
- Testing
- HBI0101 CART
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Polina Stepensky
MS (Multiple Sclerosis), NMO Spectrum Disorder
Imaging Evaluation of Central Nervous Autoimmune Diseases
Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system and the most common cause of non traumatic disability in young and middle-aged people.
- Trial name
- NCT04822623
- Testing
- MRI
- Volunteers
- 300 people
- Sponsor
- Qilu Hospital of Shandong University